A practical reference on circadian rhythm: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-08-29 and is reviewed periodically as new material appears.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
Oxytocin and vasopressin receptors are present in many other brain regions, including the amygdala, brainstem, and septum, as well as most nuclei in the hypothalamus. Because so much vasopressin and oxytocin are released at this site, studies of the supraoptic nucleus have made an important contribution to understanding how release from dendrites is regulated, and in understanding its physiological significance. Studies have demonstrated that secretin helps to facilitate dendritic oxytocin release in the SON, and that secretin administration into the SON enhances social recognition in rodents. This enhanced social capability appears to be working through secretin's effects on oxytocin neurons in the SON, as blocking oxytocin receptors in this region blocks social recognition.
=== Escape from adaptive conflict === The evolutionary model escape from adaptive conflict (EAC) proposes a possible way for new gene duplication to be fixed: conflict due to contrasting function within a single gene drives the fixation of new duplication.
post-mastectomy re-creation of the breast(s); trauma damage (blunt, penetrating), disease (breast cancer), and explantation deformity (empty breast-implant socket). congenital defect correction: micromastia, tuberous breast deformity, and Poland's syndrome. primary augmentation: the aesthetic enhancement (contouring) of the size, form, and feel of the breasts. The application of the adipose fat tissue as autologous filler for injection to correct bodily defects and for breast augmentation was developed by Melvin Bircoll by way of the fat-injection method. In 1987, the surgeon Eduardo Krulig injected fat-grafts with a syringe and a blunt-tip needle, and also used a disposable fat trap to facilitate the collection of body fat and to ensure the sterility of the harvested adipocyte tissue. The doctors J. Newman and J. Levin designed a lipo-injector gun with a gear-driven plunger for the even injection of autologous fat-tissue to the breast-implant pocket. The design of the lipo-injector gun featured a ratchet-gear for accurately emplacing the fat-grafts to the breast-implant pocket; the trigger action injected 0.1 cm3 of filler. Non-surgical, fat-graft augmentations of the breast employs adipocyte fat from elsewhere in the body of the woman (up to 300 ml of body fat) with three injections of equal volume, is injected to the subpectoral space and to the intrapectoral space of the pectoralis major muscle, and to the submammary space in order to achieve a breast of natural appearance and contour.
=== Vaso-occlusive crisis === Most people with sickle cell disease have intensely painful episodes called vaso-occlusive crises (VOC). However, the frequency, severity, and duration of these crises vary tremendously. In a VOC, the circulation of blood vessels is obstructed by sickled red blood cells, causing ischemic injuries to the tissues, inflammation, and pain. Recurrent episodes may cause irreversible organ damage. The most common and obvious symptom of a VOC is pain, which may be felt anywhere in the body but most commonly in the limbs and back. The degree of pain varies from mild to severe. Home treatment options include bed rest and hydration, and pain control using over-the-counter medication such as paracetamol or ibuprofen. More severe cases may require prescription opioids such as codeine or morphine for pain control. In 2019, crizanlizumab, a monoclonal antibody targeting P-selectin, was approved in the United States to reduce the frequency of vaso-occlusive crisis in those 16 years and older. It had also been approved in the UK and the European Union. In both cases, authorisation was subsequently withdrawn because of poor evidence of its effectiveness.
Leptin (from Greek λεπτός leptos, "thin" or "light" or "small"), also known as obese protein, is a protein hormone predominantly made by adipocytes (cells of adipose tissue). Its primary role is likely to regulate long-term energy balance. As one of the major signals of energy status, leptin levels influence appetite, satiety, and motivated behaviors oriented toward the maintenance of energy reserves (e.g., feeding, foraging behaviors). The amount of circulating leptin correlates with the amount of energy reserves, mainly triglycerides stored in adipose tissue. High leptin levels are interpreted by the brain that energy reserves are high, whereas low leptin levels indicate that energy reserves are low, in the process adapting the organism to starvation through a variety of metabolic, endocrine, neurobiochemical, and behavioral changes. Leptin is coded for by the LEP gene. Leptin receptors are expressed by a variety of brain and peripheral cell types. These include cell receptors in the arcuate and ventromedial nuclei, as well as other parts of the hypothalamus and dopaminergic neurons of the ventral tegmental area, consequently mediating feeding. Although regulation of fat stores is deemed to be the primary function of leptin, it also plays a role in other physiological processes, as evidenced by its many sites of synthesis other than fat cells, and the many cell types beyond hypothalamic cells that have leptin receptors. Many of these additional functions are yet to be fully defined.
Sources: en.wikipedia.org
Fast (rotary) potters' wheels enabled early mass production of pottery, but it was the use of the wheel as a transformer of energy (through water wheels, windmills, and even treadmills) that revolutionized the application of nonhuman power sources. The first two-wheeled carts were derived from travois and were first used in Mesopotamia and Iran around 3,000 BCE.
Cuprate superconductors are a family of high-temperature superconducting materials made of layers of copper oxides (CuO2) alternating with layers of other metal oxides, which act as charge reservoirs. At ambient pressure, cuprate superconductors are the highest temperature superconductors known.
The Moloney electrode, developed in 1921, is "designed to more accurately and rapidly determine the acidity of bacterial culture broths used in antitoxin and vaccine production." Hermann F. Schott (1904–1986) in his 1933 Ph.D. thesis gave a brief description of the Moloney electrode and its use. At Connaught Laboratories during the 1920s, Moloney dealt with the diphtheria toxin, whose preparation he directed from 1924. With Charles Beecher Weld (1899–1991), he developed the first diphtheria toxoid in North America. Moloney helped to develop a detection test for diphtheria toxin (the "Moloney test") and established methods for the detection and purification of tetanus toxin and contributed to the elucidation of its antigen structure. From 1931 he headed the "Chemistry in Relation to Hygiene" department of the School of Hygiene (dealing with microbiology) of the University of Toronto. He was part of the group that successfully developed methods for producing penicillin on a large scale during WW II. Moloney and co-workers were also able to prepare a polyvalent immune serum against gas gangrene. With Anthony L. Tosoni, he provided the basis for a new method for the production of penicillin in large quantities. Moloney was deputy director of Connaught Laboratories from 1925 until his retirement in 1961, but continued to work for the company as a researcher and consultant into his ninth decade. His last publications in the early 1970s dealt with insulin resistance and insulin as antigen. Moloney held 7 U.S.
Morrie reveals he first heard the tune being hummed from the roof, leading Nick to investigate and finding the body of a music shop owner he had met last night. This triggers another vivid vision of the music shop owner being murdered, and Nick wakes back up in the hotel room, this time with a dead woman. Nick comes to believe he murdered Virgil and many other people, and suffers more vivid hallucinations where he is taunted by the infamous serial killer Foggy Jack, who reveals he is the one who murdered Virgil and many of Nick's fans. Nick defeats Foggy Jack and then performs a concert for his fans, promising to change his hedonistic lifestyle. We All Fall Down: The final DLC story is about Arthur's former supervisor, Victoria Byng, who is the daughter of General Robert Byng, a customer of Sally's. After escaping Ollie's custody, Victoria must deal with Joy withdrawal as well as the collapse of law and order in Wellington Wells. She is armed with a whip that she can use to both attack enemies and access higher levels to avoid danger. She also has a dart gun to silently dispatch enemies and disable security defences. After escaping from Ollie and getting her whip, Victoria is able to return to town. However, with the effects of Joy having worn off, she can clearly see that the citizens of Wellington Wells are unknowingly suffering from famine and plague. She also begins seeing visions of her mother, who gives her advice on how to proceed.
Sources: en.wikipedia.org
Valve modified Alyx's AI to allow her to react to the player. Changes include commentating on objects the player manipulates or obstacles they have overcome. She also acts as an essential device in both plot exposition and directing the player's journey, often vocalizing what the player is required to do next to progress. Valve did not want Alyx to obstruct the player, and sometimes reduced her input and dialogue so players would not feel pressured or bothered by her presence. Valve placed what they described as "hero moments" to allow the player to single-handedly overcome obstacles such as challenging enemies, during which Alyx takes the role of an observer and gives the player praise. The game was extensively playtested so that Valve could gauge its effectiveness and difficulty. Episode One was made with an upgraded version of Source, with more advanced lighting effects and a new version of its facial animation/expression technology. Upgrades to enemy AI allow Combine soldiers to use tactics previously unavailable to them. For example, Combine soldiers were given the ability to crouch while being fired upon so they could duck underneath the player's line of fire. The soundtrack was composed by Kelly Bailey. The music is used sparingly; it plays primarily during scenes of major plot developments or particularly important action sequences, such as large battles or when encountering a new enemy.
Earth The HIC of mantle rocks on Earth is highly variable; and that of mantle water is around −80‰ ~ −50‰ depending on its states such as fluid, hydrous phase, hydroxyl point defect, juvenile water (from degassing of the mantle), magmatic water (water equilibrated with a magma). Sun The Sun's DHR is around 21 ± 5 × 10−6. Mars The current HIC is enriched by a factor of 5 relative to Earth's seawater due to continual losses of H in Martian atmosphere. Therefore, the δD is estimated at around +4000‰. The DHRs of Jupiter and Saturn are nearly in the order of 10−5, and the DHRs of Uranus and Neptune are closer to 10−4. Hydrogen is the most abundant element in the universe. Variations in isotopic composition of extraterrestrial materials stem from planetary accretion or other planetary processes such as atmospheric escape, and are larger for H and N than for C and O. The preservation of D-enrichment is observed in chondritic meteorites, interplanetary dust particles and cometary Volatiles. From the helium isotope abundance data, the cosmic DHR is estimated at around 20 ppm: much lower than the terrestrial DHR of 150 ppm. The enrichment of D/H from the proto-solar reservoir occurs for most of the planets except for Jupiter and Saturn, the massive gaseous planets. The DHRs of the atmospheres of Venus and Mars are ~2 × 10−2 and ~8 × 10−4 respectively. The DHRs of Uranus and Neptune are larger than that of protosolar reservoir by a factor of ~3 due to their deuterium-rich icy cores.
In addition, it was also concerned with the "modernization" of productive structures, through an ambitious program of "industrial reconversion". Obsolete or ruinous companies were closed and credits were given to companies to introduce the necessary technological improvements to make them more competitive, among other measures. The most affected sectors were the steel and shipbuilding industries, especially the large public companies inherited from Franco's regime. Not coincidentally, it was in these sectors where the most important conflicts took place, with a proliferation of clashes between workers and the forces of public order, the most serious being those of Sagunto. This program was accompanied by heavy investments in infrastructure ─ thanks mainly to the European funds that arrived after the entry into the EEC ─ which allowed Spain to equip itself with a network of highways and freeways and to start the construction of the first high-speed rail line between Madrid and Seville that started operations in 1992. The positive effects of the economic policy started to show after 1985, when the Spanish economy began a strong expansion that would last until 1992. However, during those years there was also an increase in speculative capital movements led by people linked to the world of finance who were looking for easy enrichment.
=== Hair loss disorder === The first LLLT (low-level laser device) device (at a wavelength of 635 nm) for androgenetic alopecia was approved by the FDA two decades ago. The FDA then approved a similar device (at a wavelength of 655 nm) for alopecia two years later, in 2009. Low-level laser therapy (LLLT) is the traditional FDA-approved therapy for hair loss disorders, while LEDT has become a more advanced treatment due to its safety and efficacy. The commonly used wavelengths targeting hair loss disorder are red and infrared. In-vivo studies show that the red-light LEDT at the wavelength of 655 nm contributes to dramatic improvements in the hair counts of androgenetic alopecia patients. A more recent study indicates a similar therapeutic effect of yellow-light LEDT on androgenetic alopecia and alopecia areata patients.
=== Sword === The sword is commonly thought to be a gift from the Fisher King to Perceval. This is then followed by Perceval's cousin's prophecy that the sword will break at a crucial moment. In two cases, the writers tell us that Perceval broke the sword: in Eschenbach, it fails him in his battle against his half-brother at the end of Parzival; and Gerbert de Montreuil describes how he shatters it on the gates of the "Earthly Paradise". The adventure of the broken sword is a theme originally introduced by Chrétien, who intended it as a symbol of Perceval's imperfections as a knight. The major example for his imperfection is that Perceval refused to ask about the Grail. This concept of punishment is also seen in Eschenbach's tale where Perceval is told: "your uncle gave you a sword, too, by which you have been granted since your eloquent mouth unfortunately voiced no question there." The sword remains as a plot device to both remind Perceval of how he failed to ask the healing question and as a physical reminder of the existence of "Munsalvaesche" (Eschenbach's name for Corbenic).
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.